AMRX
Amneal Pharmaceuticals Inc - Ordinary Shares - Class A

4,027
Mkt Cap
$3.85B
Volume
367,824.00
52W High
$12.68
52W Low
$6.69
PE Ratio
862.68
AMRX Fundamentals
Price
$12.17
Prev Close
$12.25
Open
$12.35
50D MA
$11.15
Beta
1.21
Avg. Volume
1.87M
EPS (Annual)
-$0.3783
P/B
-35.18
Rev/Employee
$336,621.33
Loading...
Loading...
News
all
press releases
Amneal Pharmaceuticals (NASDAQ:AMRX) Stock Rating Upgraded by Barclays
Barclays upgraded Amneal Pharmaceuticals from an "overweight" rating to a "strong-buy" rating in a report on Monday...
MarketBeat·2d ago
News Placeholder
More News
News Placeholder
JPMorgan Chase & Co. Buys 240,676 Shares of Amneal Pharmaceuticals, Inc. $AMRX
JPMorgan Chase & Co. raised its stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 22.0% during the second quarter, according to its most recent filing with the Securities and...
MarketBeat·3d ago
News Placeholder
Arrowstreet Capital Limited Partnership Sells 96,228 Shares of Amneal Pharmaceuticals, Inc. $AMRX
Arrowstreet Capital Limited Partnership decreased its stake in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 5.4% during the second quarter, according to its most recent...
MarketBeat·3d ago
News Placeholder
Amneal Pharmaceuticals, Inc. $AMRX Stock Position Lifted by Walleye Capital LLC
Walleye Capital LLC grew its holdings in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 26.9% during the second quarter, according to its most recent Form 13F filing with the...
MarketBeat·5d ago
News Placeholder
Amneal Pharma Receives FDA Approval For Cyclosporine Ophthalmic Emulsion 0.05%
(RTTNews) - Amneal Pharmaceuticals Inc. (AMRX) announced that the U.S. Food and Drug Administration has approved the company's cyclosporine ophthalmic emulsion 0.05%, a sterile, preservative-free...
Nasdaq News: Markets·11d ago
News Placeholder
Is Amneal Stock a Buy After Investment Firm Westshore Wealth Bought Over 1 Million Shares?
Key PointsWestshore Wealth initiated 1,381,910 shares in Amneal Pharmaceuticals, a position value increase of $13.83 million...
Nasdaq News: Markets·14d ago
News Placeholder
ANIP vs. AMRX: Which Niche Drugmaker Is the Better Pick?
ANI Pharmaceuticals' rare-disease momentum, led by surging Cortrophin Gel sales, sets up a stronger growth profile than its diversified rival.
Zacks·14d ago
News Placeholder
Amneal Pharmaceuticals, Inc. $AMRX Shares Sold by Segall Bryant & Hamill LLC
Segall Bryant & Hamill LLC decreased its position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 8.5% in the 2nd quarter, according to the company in its most recent filing with the...
MarketBeat·16d ago
News Placeholder
Amneal Pharmaceuticals (NASDAQ:AMRX) Reaches New 12-Month High - Time to Buy?
Amneal Pharmaceuticals (NASDAQ:AMRX) Reaches New 1-Year High - Still a Buy...
MarketBeat·17d ago
News Placeholder
Why 2025 is a Dynamic and Transformative Year for Collegium
COLL's bold buybacks, board refresh and expanding ADHD push highlight a year of strategic moves and rising momentum.
Zacks·21d ago

Latest AMRX News

View

Advertisement|Remove ads.

Advertisement|Remove ads.